ABSTRACT Seventy patients received the automatic implantable defibrillator, five original devices and 72 modified second-generation devices using only bipolar rate sensing and delivering an R wave synchronous cardioverting/defibrillating shock, for either ventricular tachycardia or fibrillation. The primary clinical arrhythmia was sustained ventricular tachycardia in 32 patients, ventricular fibrillation in 20 patients, and both ventricular tachycardia and fibrillation in 18 patients. Before implantation of the device the patients had survived 3.1 2.3 arrhythmic episodes, including 1.9 + 1.7 cardiac arrests, and had received 4.0 ± 2.1 antiarrhythmic drugs without improvement. Sixty-eight patients ultimately received devices. After a follow-up period of 8.9 ± 7.7 months (range 1 to 33), 37 patients received a total of 463 discharges. Inability to determine the precise reason for most discharges and the unpleasant nature of the discharges were the major clinical problems encountered. Complications included postoperative death (one patient), lead problems (six patients), inadequate energy requiring explanation (two patients), and pocket infection (one patient). Life- 
THE ORIGINAL AUTOMATIC implantable defibrillator used a single pair of transcardiac electrodes that both sensed arrhythmias and delivered the converting pulse discharge. Sensing was based almost entirely on a morphologic criterion called the probability density function, a measure of the time the signal spent away from the isoelectric baseline. Sufficiently rapid and sinusoidal deflections as seen in ventricular fibrillation and flutter were positively identified as life-threatening tachyarrhythmias. However, the device did not reliably detect all hypotensive ventricular tachycardia.
Initial mortality statistics derived from combined institutions (including our first 10 patients), primarily in patients receiving the original device, indicated 22.9% total and 8.5% sudden death mortality at 1 year.' Sudden cardiac death is defined in this study as instantaneous collapse or a ventricular tachyarrhythmia re- hospital. These survival statistics compare favorably with those from studies evaluating other therapies such as long-term antiarrhythmic drug administration and surgical ablation techniques.2 Recently, electrophysiologic studies have shown that in the majority of patients with sudden cardiac death, the initiating arrhythmia is rapid ventricular tachycardia. 3 4 Modifications in the design of the automatic implantable defibrillator5 6 resulted in the addition of a separate pair of sensing leads and the broadening of its application to include patients with sustained ventricular tachycardia as well as fibrillation.
We have had the opportunity to gain considerable experience with the modified device at Stanford University Hospital. We have primarily evaluated a version of device in which heart rate detection is the only criterion necessary for tachyarrhythmia sensing and have followed a rigid program of cardioversion/defibrillation testing at the time of implantation and again before hospital discharge. In this study we 
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CIRCULATION charge and the reaction to the pulse discharge were observed.
Patients were evaluated approximately every 2 months in the Cardiology Arrhythmia Study Unit Clinic or by their referring physician. In addition to a routine history and physical examination, an external analyzer device was used during these visits to measure the charge time, an indirect measure of battery energy, to ascertain the number of energy discharges the patient had received and to ensure that the device was active. A chest roentgenogram was obtained at least yearly to determine the position of the spring-coil lead. If the patient experienced frequent discharges within a short period of time, we evaluated the rhythm initiating discharges with ambulatory electrocardiographic monitoring. In most cases, continuous Holter-type monitoring was used until the patient received a pulse discharge. More recently, an electrocardiographic event recorder with a 40 sec memory was available for use.
Statistical methods. Data were expressed as mean values + SDs. Life-table analysis was performed by the Kaplan-Meier method.
Results
Preoperative data. Seventy patients received 77 devices, five first-generation AID units and 72 secondgeneration AID-BR units. The first five patients with AID devices subsequently received generator replacements for battery depletion, caused by lead fracture in one case. Fifteen patients were women and 55 were men, with a mean age of 54 ± 13 years. The underlying cardiac disease was coronary artery disease in 48 patients, congestive cardiomyopathy in eight patients, hypertrophic cardiomyopathy in one patient, mitral valve prolapse in three patients, valvular heart disease in four patients, long QT syndrome in four patients, and myasthenia gravis in one patient. There was no evidence of underlying cardiac disease in five patients. The patients' cardiac function and clinical arrhythmia data before implantation of the device are listed in tables 1 and 2. Nineteen patients had a past history of atrial tachyarrhythmias. Baseline maximal treadmill exercise testing performed in 56 patients revealed a mean maximal heart rate of 134 ± 21 beats/min and an exercise capacity of 6.2 ± 3.0 mets. Results of the baseline electrophysiologic study with induction of ventricular tachyarrhythmia revealed sustained unimorphic ventricular tachycardia in 37 patients, nonsustained ventricular tachycardia in six patients, sustained polymorphic ventricular tachycardia in 12 patients, ventricular fibrillation in 10 patients, and no inducible ventricular tachyarrhythmia in 10 patients. Details of the arrhythmia history of the 10 patients in whom sustained ventricular tachyarrhythmias were not inducible are listed in table 3. A total of 23 patients had failed amiodarone therapy before consideration of de- 
of the spring-patch system and/or replacement with a patch-patch configuration in 13 patients, and prevented implantation of the generator in two patients. The final energy delivery lead system implanted was spring-patch in 54 patients, springlarge patch in three patients, patch-patch in three patients, and large patch-large patch in eight patients. The sensing system implanted in the AID-BR systems used epicardial leads in 61 patients and endocardial leads in seven patients. Forty-one high-energy devices delivering 28 to 32 J as the first energy level were implanted. The remainder of devices delivered 23 to 27 J as the first energy level. The mean cutoff rate of the 47 AIR-BR devices was 157.8 + 22.7 beats/min (range 130.0 to 188.3).
Four of five patients with previously implanted permanent-demand pacemakers underwent pacemaker revision to prevent the pacing artifact from being sensed by the defibrillator device. One patient with a bipolar atrial unit did not require revision. One unipolar dualchamber pacemaker was initially revised to a unipolar atrial system because, intraoperatively, the defibrillator sensed the unipolar ventricular stimulus of the dual chamber pacemaker but did not sense the unipolar atrial pacing stimulus. However, postoperatively, double-sensing of the atrial pacing stimulus and the ventricular response was demonstrated. This patient ultimately received a bipolar atrial pacemaker. One unipolar ventricular unit was revised to a bipolar ventricular system with a low pulse amplitude setting. One bipolar ventricular unit and one unipolar dual chamber unit were explanted because the patients no 292 longer had bradycardia after discontinuation of amiodarone therapy.
Clinical follow-up Discharges. Patients coil leads were evident from routine chest x-rays. Sensing of myopotential signals leading to discharge of the device occurred in two patients. This was diagnosed by applying the magnet over the generator and listening to the audible sensing tone while the patient performed the physical movements previously noted to cause device discharges. Rapid erratic tones were audible during the exercise in both cases. The magnet application temporarily inactivated the device, thereby preventing discharges during the testing procedure. This problem occurred in one patient with the transvenous bipolar sensing lead and in one with myocardial screw-in sensing leads. In the patient with the trans- venous lead a large insulation break caused by a tight securing suture at the subclavian venous entry site was found at repeat operation. In the patient with the epicardial leads no insulation break was found and intraoperative lead measurements were normal. It was suspected, but not proved,that diaphragmatic or abdominal myopotentials were being sensed, since the discharges occurred when the patient arose from the supine to sitting position. Replacement with a new transvenous endocardial electrode corrected the problem of inappropriate pulse discharges in both cases. Explantation. The device was explanted in four patients. One patient with the original AID device had poor sensing of ventricular tachycardia because the original device was not designed to sense uniform rhythms having significant isoelectric components. In two patients the device demonstrated insufficient energy to either cardiovert or defibrillate. In both cases, results of intraoperative testing for defibrillation threshold indicated high thresholds for defibrillation. During predischarge electrophysiologic testing in both patients, ventricular tachycardia was induced and the delivered energy pulse accelerated the rhythm to ventricular fibrillation rather than terminating it. Moreover, the subsequent discharges delivered by the device were ineffective in terminating the ventricular fibrillation. In these two cases the devices were explanted before hospital discharge, since they were considered to be potentially harmful. In the fourth patient the device was explanted 7.5 months after implantation because of a pocket infection. The organism cultured was the same species of Serratia cultured from the patient during an episode of pneumonia 1 month before implantation.
Of the four patients undergoing device explantation, one died after 10 months because of pancreatic carcinoma while on a combination of amiodarone and quinidine. Of the other three patients, one was taking amiodarone and mexiletine after 6 months, one was taking quinidine and mexiletine after 4.5 months, and one was taking disopyramide after 6 months follow-up.
Deaths. Five patients died with the device implanted. One patient with preimplant amiodarone pulmonary toxicity died 10 days after surgical implantation because of postoperative cardiopulmonary failure. Two patients died of congestive heart failure, and one patient died 6 months after implantation during emergency surgery for replacement of a prosthetic mitral valve. Only one patient died as a consequence of ventricular tachyarrhythmia. This patient had recently begun VT = ventricular tachycardia.
Vol. 71, No. 2, February 1985 amiodarone therapy for new-onset atrial fibrillation with a rapid ventricular response that was causing defibrillator discharges. The initiation of amiodarone therapy appeared temporally related to the development of multiple paroxysmal episodes of ventricular tachycardia that recurred seconds after termination by the defibrillator. He experienced shortness of breath at home, received several defibrillator discharges, called for assistance, but was found by paramedics to be in ventricular fibrillation. The paramedics turned the device off with the magnet and performed external defibrillation and cardiopulmonary resuscitation. Ventricular tachycardia repeatedly degenerated to ventricular fibrillation, and although ultimately successfully defibrillated by paramedics, he suffered cerebral injury and died several days later in the hospital.
Survival statistics. Life-table analysis ( figure 1 ) indicated 6-and 12-month cardiovascular survival of 95.0% and 89.9%, and ventricular tachycardia or ventricular fibrillation survival of 98.2% at 6 and 12 months.
Discussion
Our study indicates an apparent improvement in survival in patients with sustained ventricular tachyarrhythmias treated with the automatic implantable cardioverter/defibrillator. Although one must be cautious when comparing survival between nonrandomized and nonconcurrent series, the patient population receiving the automatic cardioverter/defibrillator appears comparable to the overall group of patients treated for ventricular tachyarrhythmias at our institution with regard to age, sex, underlying cardiac disease, clinical arrhythmia history, and left ventricular function.2 Our previously reported series was treated in large part before the ready availability of the cardioverter/defi- brillator device, which has since served as our primary therapy for patients who do not respond to drugs. In our previously reported series of 239 patients with ventricular tachycardia or fibrillation followed for 14.8 + 13.9 months, the 1 year actuarial incidence of cardiac death was 28% and that of sudden death was 17%.2 In this group of patients the primary therapy was antiarrhythmic drugs in 157 patients, electrosurgery in 65 patients, antitachycardia pacemakers in four patients, the automatic implanted defibrillator in six patients, cardiac transplantation in five patients, and no therapy in two patients. When these patients were separated into responders and nonresponders to therapy determined from results of electrophysiologic studies, the nonresponders' 1 year mortality was approximately 40% for cardiac death and 26% for sudden death, and the responders' 1 year mortality was 16% for cardiac death and 10% for sudden death. At present, patients in whom effective antiarrhythmic drugs are identified at electrophysiologic study are not considered to be candidates for the automatic implantable cardioverter/defibrillator, so that our defibrillator population is most comparable to the previously reported nonresponder group. Therefore the 1 year cardiac death rate of 10.1% and the sudden death rate of 1.8Y% in our patients with the automatic defibrillator appear to be remarkably lower than those previously observed at our institution.
It is conceivable that concomitant coronary revascularization surgery and antiarrhythmic drug therapy contributed to enhancement of survival in this study. However, previous studies have demonstrated that arrhythmias recur after coronary artery bypass grafting.9 Concomitant antiarrhythmic drugs were only partially effective in reducing ventricular arrhythmia, or were effective only in suppressing supraventricular arrhythmias, and were similar to those given to nonresponding patients in our previous report.2 Although we do not consider the automatic cardioverter/defibrillator to be a substitute for drug therapy, since prevention of an arrhythmia is clearly preferable to termination once it has occurred, the implantable defibrillator in fact permitted us to avoid potentially toxic antiarrhythmic drug therapy in one third of our patients (generally those with infrequent episodes) and allowed us to use low drug dosages in the majority of patients requiring concomitant therapy.
In 21% of patients the spring-coil and patch electrodes were repositioned or replaced with a different electrode configuration during the implantation procedure because of insufficient energy for cardioversion or defibrillation. This high percentage is due in part to CIRCULATION V.w-our extensive testing of defibrillation thresholds intraoperatively. Testing included the induction and termination of ventricular fibrillation in patients who have experienced ventricular tachycardia only clinically, since there is an unavoidable incidence of ventricular tachycardia acceleration even with R wave synchronous pulse discharges. 8 We also prefer that an arrhythmia be terminated with the initial pulse discharge rather than by one of the three subsequent backup discharges. This extensive testing with optimization of electrode configuration may also contribute to the high survival rates in our series. Our experience indicates that it is advantageous to use either the left lateral thoracotomy approach or another approach with good exposure for implantation to allow ease in repositioning the patch lead and the use of two patches. Devices delivering a higher energy as the initial pulse were also used frequently in cases in which the results of defibrillation threshold testing were less than ideal.
Two patients requiring testing of multiple electrode configurations and use of high-energy devices because of insufficient defibrillation energy later demonlstrated pulse acceleration of ventricular tachycardia to fibrillation with inability to reliably terminate the ventricular fibrillation with subsequent discharges during predischarge electrophysiologic testing. Since both patients had clinically experienced only hypotensive ventricular tachycardia, the device was explanted because of the potential risk of harm. In two subsequent patients demonstrating similar problems of insufficient energy intraoperatively, the device was not implanted.
Detailed intraoperative testing of permanent-demand pacemakers is necessary to minimize the risk of sensing of the pacemaker stimulus by the defibrillator. In these patients the pacing stimulus was detected by the defibrillator in all unipolar systems tested. Unfortunately, this excludes the use of all currently available dual chamber systems. Very low thresholds for capture and sensing are desirable, as well as implantation of pacemakers featuring programmable pulse amplitude to minimize the chance of stimulus detection by the defibrillator. High sensitivity settings should also be used to maximize pacemaker sensing of ventricular tachyarrhythmia. Poor sensing of the ventricular arrhythmia by the demand pacemaker, manifested by simultaneous pacing, may obscure defibrillator sensing of the underlying lethal arrhythmia.
Although the incidence of lead complications may appear high compared with standard pacemaker lead implants, it must be remembered that four separate leads were used in most of our patients rather than the usual single pacemaker lead. The problem of lead miVol. 71, No. 2, February 1985 gration of the spring coil is partly attributed to the technical difficulty of securing the lead in a position without any implantation forces, quite unlike pacemaker leads. Perhaps contributing to the problem was the absence of an accessory piece for securing the lead to subcutaneous tissue. Routine chest x-ray films were valuable in detecting lead fracture and migration. Although bipolar sensing lead problems are easy to diagnose, either by noting inappropriate discharges during slow sinus rhythm or by listening to the audible sensing tones during application of the defibrillator magnet, spring-patch lead fractures may remain clinically silent, manifesting only as inability to terminate an episode of ventricular tachyarrhythmia.
To date, our major problem with the device has been the inability to easily determine the cause for the majority of pulse discharges received by the patients. Discharges in only a minority of patients have occurred with a history of palpitation and presyncope followed by a discharge and immediate sense of well being. Extensive continuous ambulatory electrocardiographic monitoring has indicated that many of the episodes of sustained ventricular tachycardia appropriately sensed and terminated by the device (usually within 12 to 15 sec) cause only moderate symptoms or may be asymptomatic. Generally the discharges must be occurring at least once a week to make it feasible to record them by continuous monitoring. Unfortunately, this requires that the patient experience one or more additional discharges to document the cause. Invariably, once the cause of frequent discharges has been determined, pharmacologic or other therapy can be initiated to eliminate further frequent discharges. Until the device incorporates a memory feature, the arrhythmias initiating each discharge cannot be tabulated. Those patients receiving a barrage of discharges during a short period of time usually experience severe but transient psychological effects. In other patients the range of reaction to receiving an occasional discharge varied considerably but was judged to be a moderate discomfort by most.
Although the mean duration of follow-up was 8.9 months, the range was quite wide. In general, those 31 patients not receiving any discharges had had the device for a short time. It is likely that our rate-only units, which do not use any electrocardiographic morphology for arrhythmia recognition, and the relatively short sense times (average 5.1 + 1.8 sec5) led to some discharges that would not have been given if other sensing criteria had been used. However, the incorporation of morphologic criteria also raises the possibility that some ventricular tchycardias above the cutoff rate may not be recognized by the device.
We attribute the high survival rates to the effectiveness of the device. However, careful preoperative evaluation and rigorous intraoperative resting of both cardioversion and defibrillation is important to optimize results. Planned improvements in the device and leads, including a retrievable memory to store the electrocardiogram before each discharge pulse, programmable discharge energy and arrhythmia cutoff rate criteria, noninvasive capability for testing spring-patch lead integrity, integrated ventricular demand pacing capabilities, lengthening of the sense time by several seconds, and use of a lead-anchoring device for suturing the spring lead, should minimize or eliminate many of the problems we have encountered. Our results reveal acceptable operative morbidity and mortality and exceptional long-term survival, suggesting that more widespread use of this device is warranted. D S Echt, K Armstrong, P Schmidt, P E Oyer, E B Stinson and R A Winkle
